
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Clinical Epidemiology and Biostatistics and 2 Pathology, Vrije University Medical Center, Amsterdam, the Netherlands
Requests for reprints: Chris J.L.M. Meijer, Department of Pathology, Vrije University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. Phone: 31-20-444-4070; Fax: 31-20-444-2964. E-mail: cjlm.meijer{at}vumc.nl
Introduction: High-risk human papillomavirus (hrHPV) DNA testing is an increasingly used instrument in cervical cancer prevention along cervical cytology. The inclusion of hrHPV testing in cervical screening requires efficient management as many hrHPV infections are transient. We investigated the potential value of hrHPV genotyping in normal and borderline/mildly dyskaryotic (BMD) smears.
Materials and Methods: From a screening population of 44,102 women in the Netherlands, we included hrHPV-positive women with a normal or BMD smear. We assessed the type-specific 18-month risk of high-grade cervical intraepithelial neoplasia (CIN).
Results: In hrHPV-positive women, 18-month risk of CIN grade 3 or invasive cancer (
CIN3) was 6% [95% confidence interval (95% CI), 4-9] after normal cytology and 20% (95% CI, 16-25) after BMD. If positive for HPV16,
CIN3 risks were 14% (95% CI, 9-21) and 37% (95% CI, 28-48), respectively. In the subset of hrHPV-positive women without HPV16, HPV18 was associated with an increased risk of high-grade CIN after normal cytology and HPV31 and HPV33 were associated with an increased risk, particularly after BMD. HPV16 and HPV18 were also associated with an increased risk of high-grade CIN in women with an hrHPV-positive normal baseline smear and a repeat normal smear at 6 months.
Discussion: HrHPV-positive women without type 16, 18, 31, or 33 had a relatively low risk of high-grade CIN. Among women with baseline normal cytology and among women with a baseline and repeat normal smear, HPV16/18positive women showed an increased risk of high-grade CIN. This warrants more aggressive management of HPV16/18positive women compared with other hrHPV-positive women. (Cancer Epidemiol Biomarkers Prev 2006;15(7):126873)
This article has been cited by other articles:
![]() |
P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hesselink, N. W. J. Bulkmans, J. Berkhof, A. T. Lorincz, C. J. L. M. Meijer, and P. J. F. Snijders Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening Program. J. Clin. Microbiol., October 1, 2006; 44(10): 3680 - 3685. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |